TSC1 is altered in 2.35% of malignant solid tumor patients with TSC1 Loss present in 0.06% of all malignant solid tumor patients [4].

TSC1 Loss is an inclusion criterion in 10 clinical trials for malignant solid tumor, of which 6 are open and 4 are closed. Of the trials that contain TSC1 Loss and malignant solid tumor as inclusion criteria, 2 are phase 1 (0 open) and 8 are phase 2 (6 open) [5].

TSC1 is altered in 2.22% of cancer patients with TSC1 Loss present in 0.06% of all cancer patients [4].

TSC1 Loss is an inclusion criterion in 2 clinical trials for cancer, of which 0 are open and 2 are closed. Of the trials that contain TSC1 Loss and cancer as inclusion criteria, 1 is early phase 1 (0 open) and 1 is phase 2 (0 open) [5].

TSC1 is altered in 1.55% of breast carcinoma patients with TSC1 Loss present in 0.03% of all breast carcinoma patients [4].

TSC1 Loss is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TSC1 Loss and breast carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

TSC1 is altered in 1.85% of non-small cell lung carcinoma patients with TSC1 Loss present in 0.03% of all non-small cell lung carcinoma patients [4].

TSC1 Loss is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TSC1 Loss and non-small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

TSC1 is altered in 0.95% of multiple myeloma patients [4].

TSC1 Loss is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain TSC1 Loss and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [5].

TSC1 is altered in 0.99% of non-hodgkin lymphoma patients [4].

TSC1 Loss is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain TSC1 Loss and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [5].

TSC1 is altered in 10.04% of infiltrating renal pelvis and ureter urothelial carcinoma patients with TSC1 Loss present in 1.5% of all infiltrating renal pelvis and ureter urothelial carcinoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for infiltrating renal pelvis and ureter urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and infiltrating renal pelvis and ureter urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 2.65% of bile duct carcinoma patients with TSC1 Loss present in 0.36% of all bile duct carcinoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 1.27% of ovarian carcinoma patients with TSC1 Loss present in 0.31% of all ovarian carcinoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 9.8% of transitional cell carcinoma patients with TSC1 Loss present in 0.29% of all transitional cell carcinoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for transitional cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and transitional cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 9.29% of bladder carcinoma patients with TSC1 Loss present in 0.07% of all bladder carcinoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 9.71% of bladder urothelial carcinoma patients with TSC1 Loss present in 0.07% of all bladder urothelial carcinoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 2.9% of colorectal carcinoma patients with TSC1 Loss present in 0.05% of all colorectal carcinoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 4.56% of melanoma patients with TSC1 Loss present in 0.05% of all melanoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 1.64% of soft tissue sarcoma patients with TSC1 Loss present in 0.05% of all soft tissue sarcoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 1.85% of lung carcinoma patients with TSC1 Loss present in 0.03% of all lung carcinoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 1.48% of adenocarcinoma of the gastroesophageal junction patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 0.96% of B-cell non-hodgkin lymphoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 Loss is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 1.83% of cervical carcinoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 1.32% of chromophobe renal cell carcinoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for chromophobe renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and chromophobe renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 1.63% of esophageal squamous cell carcinoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 0.78% of gallbladder carcinoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 1.92% of gastric adenocarcinoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 1.56% of head and neck carcinoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 0.79% of histiocytic and dendritic cell neoplasm patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 1.06% of lymphoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 4.07% of malignant uterine neoplasm patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 3.41% of non-clear cell renal cell carcinoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for non-clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and non-clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 0.64% of pancreatic carcinoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 1.5% of papillary renal cell carcinoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and papillary renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 Loss is an inclusion criterion in 1 clinical trial for renal pelvis urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and renal pelvis urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 4.55% of sarcomatoid renal cell carcinoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for sarcomatoid renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and sarcomatoid renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 7.34% of unclassified renal cell carcinoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for unclassified renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and unclassified renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 Loss is an inclusion criterion in 1 clinical trial for ureter urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and ureter urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TSC1 is altered in 11.63% of urethral urothelial carcinoma patients [4].

TSC1 Loss is an inclusion criterion in 1 clinical trial for urethral urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 Loss and urethral urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].